Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envonalkib vs Crizotinib in ALK-Positive NSCLC
NCT04009317Phase 3Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of envonalkib in anaplastic lymphoma kinase positive non-small cell lung cancer (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Progression-Free Survival up to 36 months. Status: unknown.
02
Drugs
envonalkib
03
Conditions
anaplastic lymphoma kinase positive non-small cell lung cancer
Beyond the preview
Go deeper on NCT04009317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04009317.